Profile data is unavailable for this security.
About the company
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
- Revenue in INR (TTM)63.04bn
- Net income in INR6.30bn
- Incorporated2010
- Employees14.86k
- LocationAlembic Pharmaceuticals LtdAlembic RoadVADODARA 390003IndiaIND
- Phone+91 2 652282550
- Fax+91 2 652281508
- Websitehttps://alembicpharmaceuticals.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wockhardt Ltd | 28.93bn | -3.43bn | 152.91bn | 2.39k | -- | -- | -- | 5.29 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
Sanofi India Ltd | 23.83bn | 4.30bn | 159.26bn | 2.17k | 37.06 | 23.26 | 34.03 | 6.68 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 181.53bn | 995.00 | 32.88 | -- | 19.49 | 2.65 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 182.80bn | 1.65k | 54.39 | -- | 45.87 | 11.18 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Eris Lifesciences Ltd | 22.62bn | 3.80bn | 188.70bn | 3.08k | 49.67 | -- | 30.91 | 8.34 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 194.73bn | 940.00 | 203.14 | -- | 175.57 | 14.03 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Concord Biotech Ltd | 10.38bn | 3.13bn | 198.32bn | 1.38k | 63.34 | -- | 54.05 | 19.11 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 230.31bn | 14.86k | 36.57 | -- | 25.44 | 3.65 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Laurus Labs Ltd | 50.54bn | 1.48bn | 255.64bn | 6.01k | 172.87 | -- | 46.25 | 5.06 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
Natco Pharma Ltd. | 42.21bn | 16.37bn | 257.25bn | 4.02k | 15.72 | -- | 14.10 | 6.09 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Pfizer Ltd | 22.25bn | 6.09bn | 263.45bn | 1.72k | 43.30 | -- | 39.33 | 11.84 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 277.60bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
Gland Pharma Ltd | 58.58bn | 7.22bn | 279.84bn | 4.22k | 38.75 | -- | 25.60 | 4.78 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 280.54bn | 5.31k | 48.84 | -- | 38.18 | 7.81 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Piramal Pharma Ltd | 83.73bn | 277.60m | 292.00bn | 6.72k | 1,050.21 | -- | 37.47 | 3.49 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 305.15bn | 1.05k | 126.76 | -- | 103.12 | 32.65 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Holder | Shares | % Held |
---|---|---|
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 8.50m | 4.33% |
DSP Asset Managers Pvt. Ltd.as of 31 Jul 2024 | 8.17m | 4.16% |
Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2024 | 3.47m | 1.76% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 1.83m | 0.93% |
Axis Asset Management Co. Ltd.as of 31 Jul 2024 | 1.45m | 0.74% |
Dimensional Fund Advisors LPas of 04 Jul 2024 | 982.32k | 0.50% |
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Jul 2024 | 755.96k | 0.39% |
BlackRock Fund Advisorsas of 04 Jul 2024 | 749.96k | 0.38% |
Union Asset Management Co. Pvt Ltd.as of 30 Jun 2024 | 633.73k | 0.32% |
Edelweiss Asset Management Ltd.as of 31 Jul 2024 | 564.61k | 0.29% |